Select your products and services :
Select your country :
Americas
Europe
Asia and South Pacific
Middle East and Africa

Update your choices | BU : Life Science | Country : USA

mAb - Hybridoma’s development

mAb- Hybridoma’s development

Eurogentec develops murine hybridomas in 16-19 weeks following a stepwise approach with testing sample phases. A reporting is sent after each phase and discussed with the customer for potential adaptation. If no positive hybridoma is obtained after phase 3, only phase 1 will be charged.

However, a personalised procedure may be designed and adapted to your needs.

mAb – Hybridoma’s generation Programme Overview




Programme Details

Project Development:

Prior to project initiation, you can benefit from our personalised project proposals and expertise.

Starting Material:

You send us:

  • Your purified protein
  • Or your peptide sequence
  • Or your protein’s accession number
  • Or other antigen

Phase I: Immunisation ~ 6 weeks

  • A minimum of four mice (6-8 weeks old) are used for immunisation.
  • Preimmune serum is taken on day 0.
  • The first injection on day 0 with equal parts (v/v) of complete Freund's adjuvant and antigen.
    The following boosts are carried out with equal parts (v/v) incomplete Freund's adjuvant and antigen on days 21 and 36 with an additional final boost prior to fusion.
  • You receive an ELISA report against the supplied antigen and serum sample.
  • Selection of the best responding host on the basis of Customer's test results.

Phase II: Fusion/Hybridoma production~ 2-3 weeks

The splenic lymphocytes of the best responding animal will be fused with the cell line Sp2/O-Ag-14 using PEG (polyethylene glycol), and the resulting hybridomas will be seeded in eight 96-well plates in HAT medium.

  • You receive a Fusion report.

Phase III: Screening for positive hybridomas ~ 4-5 weeks

  • Screening for positive antibody producing hybridomas (ELISA against the target antigen)
  • Positive colonies are expanded and tested for antibody production
    On request, positive colonies can also be screened against other antigens for cross-reactivity or against a specific region of the antigen of interest Different screening techniques are available and can be used on request. Please contact us for more information
  • You receive a screening report, an ELISA against your antigen, a delivery of >1 ml positive supernatants (Maximum 30) for screening confirmation and additional tests.

Phase IV: Cloning and isotyping of positive hybridomas ~ 4-5 weeks

  • The specific hybridomas selected by the customer at the end of the Phase III are cloned by serial dilution.
  • Positive hybridomas are collected in vials
  • Monoclonal antibody isotype is determined
  • You receive hybridomas ELISA and isotyping report, > 10 ml of supernatant from 1-2 positive clones and frozen hybridomas are delivered.

How to start

To qualify and build your project or to receive a quotation adapted to your needs, please contact your local representative or send us an e-mail at monoclonals@eurogentec.com

Need a trustable partner for your hybridoma development?

Visit our large scale antibody project dedicated website.


Support Area


We use cookies to ensure the best experience on our website. By continuing to use this website, you consent to our cookie policy.